Uromodulin and its association with urinary metabolites: the German Chronic Kidney Disease Study. Issue 1 (24th May 2022)

• Record Type: Journal Article
• Authors: Bächle, Helena; Sekula, Peggy; Schlosser, Pascal; Steinbrenner, Inga; Cheng, Yurong; Kotsis, Fruzsina; Meiselbach, Heike; Stockmann, Helena; Schönherr, Sebastian; Eckardt, Kai-Uwe; Devuyst, Olivier; Scherberich, Jürgen; Köttgen, Anna; Schultheiss, Ulla T
• Is Part Of: Nephrology dialysis transplantation. Volume 38:Issue 1(2023)
• Page Start: 70
• Page End: 79
• Publication Date: 2022-05-24
• Subjects: CKD -- metabolites -- nephron mass -- uromodulin; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfac187
• Languages: English
• ISSNs: 0931-0509

Abstract

ABSTRACT: Background: The progression of chronic kidney disease (CKD), a global public health burden, is accompanied by a declining number of functional nephrons. Estimation of remaining nephron mass may improve assessment of CKD progression. Uromodulin has been suggested as a marker of tubular mass. We aimed to identify metabolites associated with uromodulin concentrations in urine and serum to characterize pathophysiologic alterations of metabolic pathways to generate new hypotheses regarding CKD pathophysiology. Methods: We measured urinary and serum uromodulin levels (uUMOD, sUMOD) and 607 urinary metabolites and performed cross-sectional analyses within the German Chronic Kidney Disease study ( N = 4628), a prospective observational study. Urinary metabolites significantly associated with uUMOD and sUMOD were used to build weighted metabolite scores for urine (uMS) and serum uromodulin (sMS) and evaluated for time to adverse kidney events over 6.5 years. Results: Metabolites cross-sectionally associated with uromodulin included amino acids of the tryptophan metabolism, lipids and nucleotides. Higher levels of the sMS [hazard ratio (HR) = 0.73 (95% confidence interval 0.64; 0.82), P = 7.45e-07] and sUMOD [HR = 0.74 (95% confidence interval 0.63; 0.87), P = 2.32e-04] were associated with a lower risk of adverse kidney events over time, whereas uUMOD and uMS showed the same direction of association but were not significant. Conclusions: We identified urinary metabolites associated with urinary and serum uromodulin. The sUMOD and the sMS were associated with lower risk of adverse kidney events among CKD patients. Higher levels of sUMOD and sMS may reflect a higher number of functional nephrons and therefore a reduced risk of adverse kidney outcomes.